Observation Versus Treatment for Patients with CLL

Opinion
Video

Medical professionals discuss factors influencing the decision between observation and treatment, optimal diagnostic methods for chronic lymphocytic leukemia (CLL), and key markers to assess in patients with suspected CLL.

Recent Videos
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
A 2-way communication between providers and patients may help facilitate dose modifications to help better manage adverse effects.
Related Content
Data from a phase 1 trial may support additional clinical studies of CT0596 in relapsed/refractory multiple myeloma.

Novel Anti-BCMA Agent Shows Preliminary Responses in R/R Multiple Myeloma

Russ Conroy
December 20th 2025
Article

Data from a phase 1 trial may support additional clinical studies of CT0596 in relapsed/refractory multiple myeloma.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Zanubrutinib led to a 72% reduction in the risk of disease progression or death vs bendamustine/rituximab in this CLL/SLL population.

Zanubrutinib Exhibits Superior Long-Term Efficacy in First-Line CLL/SLL

Kristi Rosa
December 10th 2025
Article

Zanubrutinib led to a 72% reduction in the risk of disease progression or death vs bendamustine/rituximab in this CLL/SLL population.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Data from the BRUIN-CLL-313 study may support pirtobrutinib as a new potential standard of care for those with untreated CLL or SLL.

Pirtobrutinib Improves PFS in Treatment-Naive CLL/SLL

Sabrina Serani
December 9th 2025
Article

Data from the BRUIN-CLL-313 study may support pirtobrutinib as a new potential standard of care for those with untreated CLL or SLL.

Novel Treatment Displays Tolerability in Relapsed/Refractory B-Cell ALL

Novel Treatment Displays Tolerability in Relapsed/Refractory B-Cell ALL

Roman Fabbricatore
December 9th 2025
Article

A total of 45% of patients with B-cell acute lymphoblastic leukemia experienced cytokine release syndrome while receiving treatment with MK-1045, of which 3% experienced grade 3 events.